To order this 350+ page report, which features 140+ figuresand 170+ tables, please visit this link
Key Market Insights
§ More than 150 industry players across the world arepresently engaged in evaluating the potential of nearly 300 next generationimmune checkpoint modulators for the treatment of multiple disease indications
§ The pipeline features a variety of marketed / clinicalstage therapies, targeting a number of different types of immune checkpointsand being investigated for administration via different routes
§ In the last few years, over 600 clinical studies of varioustypes of immune checkpoint modulation-based therapies, involving nearly 90,000patients across different centers / hospitals, have been initiated worldwide
§ In the pursuit of obtaining an edge within this emergingand highly competitive market landscape, developers are actively exploring thetherapeutic potential of novel immune checkpoints, beyond PD-L1, PD-1 andCTLA-4
§ Over time, big pharma players haveinitiated product development programs focused on immune checkpoint modulationfor treating various oncological indications, investing significant capital,time and effort
§ Several organizations have extended financial support toaid research efforts in this domain; the current focus is on investigation ofnovel immune checkpoint pathways / targets
§ The growing interest in this fieldis also reflected by the 120+ partnerships have been signed in the last twoyears, involving both international and indigenous stakeholders
§ The future market, based on the revenue generationpotential of marketed and late stage therapies, is anticipated to bedistributed across different disease areas, mechanisms and key geographicalregions
§ In the long term, the opportunity is likely to be segmentedacross diverse therapeutic modalities, immune checkpoint targets and routes ofadministration
For more information, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
